Research Project

研究项目

• 批准号: 8033909
• 负责人: Christi A Patten
• 金额: $ 55.4万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8033909
• 关键词: Abstinence; Advisory Committees; Alaska Native; American Indian and Alaska Native; Arctic Regions; Biological Markers; Birth; Blood specimen; Butanones; Cancer Etiology; Carcinogen exposure; Carcinogens; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cessation of life; Cigarette Smoker; Clinic; Clinical; Communities; Cotinine; Doctor of Philosophy; Enrollment; Evaluation; Exposure to; Feedback; Future; Health; Individual; Infant; Intervention; Interview; Investigation; Malignant Neoplasms; Malignant neoplasm of lung; Medical center; Mothers; Native-Born; Neonatal; Nicotine; Nitrosamines; Participant; Phase; Pilot Projects; Pregnancy; Pregnant Women; Prevalence; Public Health; Randomized; Research Project Grants; Risk; Sampling; Smoke; Smokeless Tobacco; Smoker; Specimen; Testing; Tobacco; Tobacco Use Cessation; Tobacco use; Urine; Woman; Work; base; biobank; cancer health disparity; cancer prevention; cigarette smoking; design; effective intervention; men; neonate; novel; preference; pregnant; programs; tobacco exposure

Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women Project Leader: Christi Patten, Ph.D. Mayo Clinic Rochester MN Project Summary: Developing effective tobacco cessation inten/entions during pregnancy for American Indian and Alaska Native people is a national priority and will contribute to the U.S. public health objective of reducing tobaccorelated cancer health disparities. The proposed project builds on our successful partnership with the Alaska Native community and previous work with Alaska Native pregnant women. We propose to develop and test a novel biomarker feedback intervention relating cotinine levels in the urine of pregnant women with the woman and infant's likely exposure to the tobacco specific nitrosamine and carcinogen 4-(methylnitrosamino)-1 -(3-pyridyl)-1-butanone) (NNK). This 5-year project will be conducted in three phases. In Phase 1 we will utilize a non-randomized, clinical observational trial to examine biomarkers of nicotine and carcinogen exposure (urine cotinine and total NNAL [a metabolite of NNK], respectively) among 150 maternal-infant pairs with assessments conducted during pregnancy and at delivery. In Phase 2, we will obtain qualitative feedback on the findings from Phase 1 through individual interviews conducted with 32 women who use tobacco to develop the biomarker feedback intervention messages. Phase 3 will consist of a formative evaluation of the biomarker feedback intervention with 80 pregnant women using a two-group randomized design to assess the intervention's feasibility and acceptability, and the biochemically confirmed abstinence rate at the end of pregnancy. All phases of the project will be guided by a Community Advisory Committee. Each phase is an important step to advance our understanding of the potential for biomarker feedback as a strategy to help Alaska Native pregnant women quit tobacco use. The potential reach of the intervention is significant from a public health perspective as over 600 tobacco users deliver each year at the Alaska Native Medical Center in Anchorage where the proposed project will take place. Developing effective interventions for tobacco cessation during pregnancy is important to reduce adverse health consequences for the mother and neonate and future risk of tobacco-caused cancers.

生物标志物反馈促进孕妇戒烟 阿拉斯加土著妇女 项目负责人： Christi Patten博士 马约诊所罗切斯特明尼苏达州 项目概要： 为美国印第安人和阿拉斯加原住民制定有效的怀孕期间戒烟计划是国家的优先事项，将有助于美国减少烟草相关癌症健康差异的公共卫生目标。拟议的项目建立在我们与阿拉斯加原住民社区的成功伙伴关系以及以前与阿拉斯加原住民孕妇的合作基础上。我们建议开发和测试一种新的生物标志物反馈干预，将孕妇尿液中的可替宁水平与妇女和婴儿可能暴露于烟草特异性亚硝胺和致癌物4-（甲基亚硝胺）-1 -（3-吡啶基）-1-丁酮（NNK）相关。这个为期五年的项目将分三个阶段进行。在第1阶段，我们将利用一项非随机、临床观察性试验，在150对母婴中检查尼古丁和致癌物暴露的生物标志物（分别为尿可替宁和总NNAL [NNK的代谢产物]），并在妊娠期间和分娩时进行评估。在第二阶段，我们将通过对32名使用烟草的妇女进行个人访谈，获得第一阶段调查结果的定性反馈，以制定生物标志物反馈干预信息。第3阶段将包括使用两组随机设计对80名孕妇进行生物标志物反馈干预的形成性评估，以评估干预的可行性和可接受性，以及妊娠结束时经生化证实的禁欲率。该项目的所有阶段都将由社区咨询委员会指导。每个阶段都是一个 重要的一步是促进我们对生物标志物反馈作为帮助阿拉斯加原住民孕妇戒烟策略的潜力的理解。从公共卫生的角度来看，干预措施的潜在影响是重大的，因为每年有600多名烟草使用者在安克雷奇的阿拉斯加土著医疗中心分娩，拟议的项目将在那里进行。制定有效的怀孕期间戒烟干预措施对于减少对母亲和新生儿的不良健康后果以及未来烟草引起的癌症风险至关重要。